Description
Ado-Trastuzumab Emtansine (Kadcyla®) – HER2-Positive Breast Cancer Treatment
Ado-trastuzumab emtansine (brand name Kadcyla®) is an advanced targeted therapy used in the treatment of HER2-positive breast cancer. Kadcyla® is an antibody-drug conjugate (ADC) that combines trastuzumab, a HER2-targeted monoclonal antibody, with DM1 (emtansine), a chemotherapy agent. This combination allows the medicine to precisely deliver chemotherapy inside HER2-positive cancer cells while limiting damage to surrounding healthy cells.
At Oncomed Pharmacy, we provide authentic Kadcyla® (ado-trastuzumab emtansine) injections, sourced from trusted manufacturers, ensuring reliable access to life-saving cancer medicines at affordable prices.
Indications & Uses
Kadcyla® is prescribed for:
- Metastatic HER2-positive breast cancer in patients previously treated with trastuzumab and taxane-based chemotherapy.
- Early-stage HER2-positive breast cancer in patients with residual disease after neoadjuvant therapy.
Key Benefits
- Targets and destroys HER2-positive cancer cells directly
- Reduces systemic side effects compared to standard chemotherapy
- Proven to improve survival and reduce cancer recurrence
- Administered by intravenous infusion every 3 weeks under medical supervision
Why Choose Kadcyla® from Oncomed Pharmacy?
- 100% genuine oncology medicines with quality assurance
- Competitive Kadcyla® price with cost-effective options
- Secure cold-chain storage and delivery for medicine safety
- Professional pharmacist support and patient guidance
Important Safety Information
- Dosage & Administration: IV infusion every 3 weeks, prescribed and monitored by a healthcare professional.
- Possible Side Effects: Fatigue, nausea, headache, low platelet count, liver enzyme changes, neuropathy, or infusion reactions.
- Precautions: Regular monitoring of heart and liver function is required. Not recommended for pregnant or breastfeeding women.
Reviews
There are no reviews yet.